EGFR‐TKIs such as gefitinib, erlotinib, and afatinib have been established as standard first‐line drug therapies in advanced NSCLC patients harboring EGFR mutations on the basis of a number of phase III trials.5, 6, 7, 8, 9, 10, 11. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.